UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule 13G
Under the Securities Exchange Act of 1934
(Amendment No. 5)*
HOOKIPA PHARMA INC.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
43906K 100
(CUSIP Number)
December 20, 2023
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
| * | The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 43906K 100
| 1 |
NAMES OF REPORTING PERSONS
Gilead Sciences, Inc. | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
| |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
State of Delaware | |||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: |
5 | SOLE VOTING POWER
18,759,465 | ||||
| 6 | SHARED VOTING POWER
-0- | |||||
| 7 | SOLE DISPOSITIVE POWER
18,759,465 | |||||
| 8 | SHARED DISPOSITIVE POWER
-0- | |||||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
18,759,465 | |||||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
☐ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
19.4%(1) | |||||
| 12 | TYPE OF REPORTING PERSON
CO | |||||
| (1) | Based on 81,550,590 shares of the common stock of the Issuer (the “Common Stock”) issued and outstanding as of November 2, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the “SEC”) on November 9, 2023. |
2 of 5
| Item 1(a). | Name of Issuer: |
The name of the issuer is HOOKIPA Pharma Inc. (the “Issuer”).
| Item 1(b). | Address of Issuer’s Principal Executive Offices: |
The Issuer’s principal executive offices are located at 350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY 10118.
| Item 2(a). | Name of Person Filing: |
This Amendment No. 5 to Schedule 13G is being filed by Gilead Sciences, Inc. (the “Reporting Person”).
| Item 2(b). | Address of Principal Business Office or, if none, Residence: |
The address of the principal business office of the Reporting Person is 333 Lakeside Drive, Foster City, California, 94404.
| Item 2(c). | Citizenship: |
The Reporting Person is incorporated in the State of Delaware.
| Item 2(d). | Title of Class of Securities: |
Common Stock, par value $0.0001 per share
| Item 2(e). | CUSIP No.: |
43906K 100
| Item 3. | If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
Not applicable.
| Item 4. | Ownership. |
| (a) | Amount beneficially owned: |
18,759,465
| (b) | Percent of class (2): |
19.4%
| (2) | Based on 81,550,590 shares of the Common Stock issued and outstanding as of November 2, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC on November 9, 2023. |
3 of 5
| (c) | Number of shares as to which the person has: |
| (i) | Sole power to vote or to direct the vote: |
18,759,465
| (ii) | Shared power to vote or to direct the vote: |
-0-
| (iii) | Sole power to dispose or to direct the disposition of: |
18,759,465
| (iv) | Shared power to dispose or to direct the disposition of: |
-0-
| Item 5. | Ownership of 5 Percent or Less of a Class. |
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
| Item 6. | Ownership of More Than 5 Percent on Behalf of Another Person. |
Not applicable.
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
Not applicable.
| Item 8. | Identification and Classification of Members of the Group. |
Not applicable.
| Item 9. | Notice of Dissolution of Group. |
Not applicable.
| Item 10. | Certifications. |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
4 of 5
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Amendment No. 5 to Schedule 13G is true, complete and correct.
Dated: December 22, 2023
| GILEAD SCIENCES, INC. | ||
| By: | /s/ Andrew D. Dickinson | |
| Name: | Andrew D. Dickinson | |
| Title: | Executive Vice President and Chief Financial Officer | |
5 of 5